Руководство по диагностике, профилактике и лечению сердечно-сосудистых осложнений противоопухолевой терапии. Части II–V

1. Чазова И.Е., Тюляндин С.А., Виценя М.В. и др. Руководство по диагностике, профилактике и лечению сердечно-сосудистых осложнений противоопухолевой терапии. Часть I. Системные гипертензии. 2017; 14 (3): 6–20. / Chazova I.Ye., Tyulyandin S.A., Vicenia M.V. et al. Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I. Systemic Hypertension. 2017; 14 (3): 6–20. [in Russian]
2. Herrmann J, Lerman A. Vascular toxicities of cancer therapies. In: Clinical Cardio-oncology. Elsevier 2016; p. 163–84.
3. Polk A, Vistisen K, Vaage-Nilsen M et al. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014; 15: 47.
4. De Forni M, Bugat R, Sorbette F et al. Cardiotoxicity of continuous intravenous infusion of 5-fluorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases. Bull Cancer 1990; 77 (5): 429–38.
5. Südhoff T, Enderle MD, Pahlke M et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 2004; 15 (4): 661–4.
6. Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Int Med J 2010; 40 (4): 303–7.
7. Grunwald MR, Howie L, Diaz LA Jr. Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature. J Clin Oncol 2012; 30 (2): e11–e14.
8. Smith SA, Auseon AJ. Chemotherapy-induced takotsubo cardiomyopathy. Heart Fail Clin 2013; 9 (2): 233–42.
9. Cerny J, Hassan A, Smith C et al. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. Clin Colorectal Cancer 2009; 8 (1): 55–8.
10. Ambrosy AP, Kunz PL, Fisher GA et al. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol 2012; 110 (11): 1623–6.
11. Boyle JJ, Wilson B, Bicknell R et al. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol 2000; 192 (2): 234–42.
12. Coward J, Maisey N, Cunningham D. The effects of capecitabine in Raynaud’s disease: a case report. Ann Oncol 2005; 16 (5): 835–6.
13. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58 (4): 487–93.
14. Polk A, Vaage-Nilsen M, Vistisen K et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013; 39 (8): 974–84.
15. Rowinsky EK, McGuire WP, Guarnieri T et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9 (9): 1704–12.
16. Schrader C, Keussen C, Bewig B et al. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res 2005; 10 (11): 498–501.
17. Shah K, Gupta S, Ghosh J et al. Acute non-ST elevation myocardial infarction following paclitaxel administration for ovarian carcinoma: a case report and review of literature. J Cancer Res Ther 2012; 8 (3): 442–4.
18. Berliner S, Rahima M, Sidi Y et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990; 8 (6): 583–6.
19. Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anti Cancer Drugs 2008; 19 (9): 927–9.
20. Karabay KO, Yildiz O, Aytekin V. Multiple coronary thrombi with cisplatin. J Invasive Cardiol 2014; 26 (2): E18–E20.
21. Togna GI, Togna AR, Franconi M et al. Cisplatin triggers platelet activation. Thromb Res 2000; 99 (5): 503–9.
22. Dieckmann KP, Gerl A, Witt J et al. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol 2010; 21 (8): 1607–11.
23. Ito D, Shiraishi J, Nakamura T et al. Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy. Heart Vessels 2012; 27 (6): 634–8.
24. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18 (8): 1725–32.
25. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treat-ment for testicular cancer. J Clin Oncol 2003; 21 (8): 1513–23.
26. Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28 (30): 4649–57.
27. Feldman DR, Schaffer WL, Steingart RM. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Cancer Netw 2012; 10 (4): 537–44.
28. Gietema JA, Meinardi MT, Messerschmidt J et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355 (9209): 1075–6.
29. Nuver J, Smit AJ, Sleijfer DT et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40 (5): 701–6.
30. Oh JH, Baum DD, Pham S et al. Long-term complications of platinum-based chemotherapy W.J. in testicular cancer survivors. Med Oncol 2007; 24 (2): 175–81.
31. Kachel DL, Martin. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther 1994; 268 (1): 42–6.
32. Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141 (6): 758–63.
33. Katayama M, Imai Y, Hashimoto H et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol 2009; 54 (2): 330–4.
34. Stefenelli T, Kuzmits R, Ulrich W et al. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J 1988; 9 (5): 552–6.
35. Soultati A, Mountzios G, Avgerinou C et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev 2012; 38 (5): 473–83.
36. Schwarzer S, Eber B, Greinix H et al. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J 1991; 12 (6): 748–50.
37. Doll DC, List AF, Greco FA et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105 (1): 48–51.
38. Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987; 19 (3): 253–6.
39. Panella M, Ross JE, Garvin K et al. Cardiac sudden death as a result of acute coronary artery thrombosis during chemotherapy for testicular carcinoma. J Forensic Sci 2010; 55 (5): 1384–8.
40. Gallagher H, Carroll WM, Dowd M et al. The effects of vinblastine on endothelial cells. Endothelium 2008; 15 (1): 9–15.
41. Schutz FA, Je Y, Azzi GR et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011; 22 (6): 1404–12.
42. Ranpura V, Hapani S, Chuang J et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010; 49 (3): 287–97.
43. Chen XL, Lei YH, Liu CF et al. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One 2013; 8 (6): e66721.
44. Choueiri TK, Schutz FA, Je Y et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010; 28 (13): 2280–5.
45. Qi WX, Shen Z, Tang LN et al. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis. Crit Rev Oncol Hematol 2014; 92 (2): 71–82.
46. Kappers MH, van Esch JH, Sluiter W et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010; 56 (4): 675–81.
47. Winnik S, Lohmann C, Siciliani G et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis–implications for cardiovascular safety. Int J Cardiol 2013; 168 (3): 2453–61.
48. Kappers MH, Smedts FM, Horn T et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 2011; 58 (2): 295–302.
49. Kappers MH, de Beer VJ, Zhou Z et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012; 59 (1): 151–7.
50. Arima Y, Oshima S, Noda K et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol 2009; 54 (3): 512–5.
51. Porto I, Leo A, Miele L et al. A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol 2010; 7 (8): 476–80.
52. Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz 2011; 36 (4): 348–51.
53. Franco TH, Khan A, Joshi V et al. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag 2008; 4 (6): 1367–70.
54. Numico G, Sicuro M, Silvestris N et al. Takotsubo syndrome in a patient treated with sunitinib for renal cancer. J Clin Oncol 2012; 30 (24): e218–e220.
55. Sen F, Yildiz I, Basaran M et al. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib. J BUON 2013; 18 (3): 775–81.
56. Chintalgattu V, Rees ML, Culver JC et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med 2013; 5 (187): 187ra69.
57. Van der Veldt AA, de Boer MP, Boven E et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anti Cancer Drugs 2010; 21 (4): 439–46.
58. Pantaleo MA, Mandrioli A, Saponara M et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer 2012; 12: 231.
59. Ropert S, Vignaux O, Mir O, Goldwasser F. VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption. Invest New Drugs 2011; 29 (6): 1497–9.
60. Meyer T, Robles-Carrillo L, Robson T et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009; 7 (1): 171–81.
61. Aichberger KJ, Herndlhofer S, Schernthaner GH et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86 (7): 533–9.
62. Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012; 12 (5): 337–40.
63. Levato L, Cantaffa R, Kropp MG et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol 2013; 90 (6): 531–2.
64. Cortes JE, Kantarjian H, Shah NP et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367 (22): 2075–88.
65. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011; 86 (7): 610–1.
66. Coon EA, Zalewski NL, Hoffman EM et al. Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol 2013; 88 (6): 534–5.
67. Breccia M, Colafigli G, Molica M et al. Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. Am J Hematol 2015; 90 (5): E100–E101.
68. Chislock EM, Ring C, Pendergast AM. Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci U S A 2013; 110 (30): 12432–7.
69. Teragawa H, Hondo T, Amano H et al. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996; 37 (6): 905–15.
70. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011; 37 (4): 300–11.
71. Kruit WH, Eggermont AM, Stoter G. Interferon-alpha induced Raynaud’s syndrome. Ann Oncol 2000; 11 (11): 1501–2.
72. Al-Zahrani H, Gupta V, Minden MD et al. Vascular events associated with alpha interferon therapy. Leuk Lymphoma 2003; 44 (3): 471–5.
73. Thacker SG, Zhao W, Smith CK et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 2012; 64 (9): 2975–85.
74. Lancellotti P, Nkomo VT, Badano LP et al. European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013; 14: 721–40.
75. Zamorano JL, Lancellotti Р, Munoz DR et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; 37: 2768–801.
76. Piccirillo JF, Tierney RM, Costas I et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291 (20): 2441–7.
77. Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Диагностика и лечение артериальной гипертонии. Клинические рекомендации. Кардиологич. вестн. 2015; 1: 3–31. / Chazova I.E., Oshchepkova E.V., Zhernakova Iu.V. Diagnostika i lechenie arterial'noi gipertonii. Klinicheskie rekomendatsii. Kardiologich. vestn. 2015; 1: 3–31. [in Russian]
78. Colt JS, Schwartz K, Graubard BI et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 2011; 22: 797–804.
79. Milan A, Puglisi E, Ferrari L et al. Arterial hypertension and cancer. Int J Cancer 2014; 134: 2269–77.
80. Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20: 807–15.
81. Qi WX, He AN, Shen Z et al. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 2013; 76: 348–57.
82. Qi WX, Lin F, Sun YJ et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a metaanalysis. Cancer Chemother Pharmacol 2013; 71: 431–9.
83. Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23: 460–8.
84. Li Y, Li S, Zhu Y et al. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2014; 16 (3): 177–85.
85. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009; 48: 9–17.
86. Qi WX, Shen Z, Lin F et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 2013; 75: 919–30.
87. Wang Z, Xu J, Nie W et al. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol 2014; 70: 225–31.
88. Qi WX, Fu S, Zhang Q et al. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis. J Cancer Res Ther 2016; 12 (2): 775–81.
89. Qi WX, Shen Z, Tang LN et al. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. Clin Drug Invest 2014; 34 (4): 231–40.
90. Wicki A, Hermann F, Prкtre V et al. Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study. Oncol Res Treat 2014; 37: 230–6.
91. Hamnvik OP, Choueiri TK, Turchin A et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015; 121: 311–9.
92. Tomita Y, Uemura H, Fujimoto H et al. Japan Axitinib Phase II Study Group. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 2011; 47: 2592–602.
93. Small HY, Montezano AC, Rios FJ et al. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol 2014; 30: 534–43.
94. Mourad JJ, Des Guetz G, Debbabi H et al. Blood pressure rise following angiogenesis inhibition bybevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927–34.
95. Facemire CS, Nixon AB, Griffiths R et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009; 54: 652–8.
96. Ciuffetti G, Schillaci G, Innocente S et al. Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J Hypertens 2003; 21: 2297–303.
97. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008; 266 (1): 37–52.
98. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129–36.
99. Scartozzi M, Galizia E, Chiorrini S et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009; 20 (2): 227–30.
100. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with sunitinib. J Natl Cancer Inst 2011; 103 (9): 763–73.
101. De Souza VB, Silva EN, Ribeiro ML et al. Hypertension in Patients with Cancer. Arq Bras Cardiol 2015; 104 (3): 246–52.
102. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
103. Maitland ML, Bakris GL, Black HR et al. Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.
104. Herrmann J, Yang EH, Iliescu CA et al. Vascular Toxicities of Cancer Therapies The Old and the New – An Evolving Avenue. Circulation 2016; 133: 1272–89.
105. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151–6.
106. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687–91.
107. McKay RR, Rodriguez GE, Lin X et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015; 21 (11): 2471–9.
108. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006; 48: 622–7.
109. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010; 7: 564–75.
110. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231–47.
111. Tamargo J, Caballero R, Delpon E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 2015; 38: 129–52.
112. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsedacute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–60.
113. Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associatedwith tyrosine kinase inhibitors. Oncologist 2013; 18: 900–8.
114. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013; 36: 295–316.
115. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007; 25: 3362–71.
116. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillationin cancer. J Am Coll Cardiol 2014; 63: 945–53.
117. Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventriculararrhythmias and the prevention of sudden cardiac death: the Task Forcefor the Management of Patients with Ventricular Arrhythmias and the Preventionof Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsedby: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793–867.
118. Al-Khatib SM, LaPointe NM, Kramer JM et al. What clinicians should knowabout the QT interval. JAMA 2003; 289: 2120–7.
119. Bates SE, Rosing DR, Fojo T et al. Challenges of evaluating the cardiaceffects of anticancer agents. Clin Cancer Res 2006; 12: 3871–4.
120. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrialfibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893–962.
121. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467–507.
122. Larsen TB, Nielsen PB, Skjoth F et al. Non-vitamin K antagonistoral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One 2014; 9 (12): e114445.
123. Limsuwan A, Pakakasama S, Rochanawutanon M et al. Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology 2006; 105: 188–94.
124. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009; 33: 861–4.
125. Mattei D, Feola M, Orzan F et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009; 43: 967–8.
126. Montani D, Bergot E, Günther S et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128–37.
127. Dumitrescu D, Seck C, ten Freyhaus H et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011; 38: 218–20.
128. Guignabert C, Montani D. Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. Eur Respir J 2013; 41: 3–4.
129. Galie N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67–119.
130. Simonneau G, Gatzoulis MA, Adatia I et al. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25): 34–41.
131. Ranchoux B, Gunther S, Quarck R et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol 2015; 185: 356–71.
132. Чазова И.Е., Авдеев С.Н., Царева Н.А. и др. Клинические рекомендации по диагностике и лечению легочной гипертонии. Тер. архив. 2014; 9: 4–23. / Chazova I.E., Avdeev S.N., Tsareva N.A. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniiu legochnoi gipertonii. Ter. arkhiv. 2014; 9: 4–23. [in Russian]

________________________________________________

1. Chazova I.Ye., Tyulyandin S.A., Vicenia M.V. et al. Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I. Systemic Hypertension. 2017; 14 (3): 6–20. [in Russian]
2. Herrmann J, Lerman A. Vascular toxicities of cancer therapies. In: Clinical Cardio-oncology. Elsevier 2016; p. 163–84.
3. Polk A, Vistisen K, Vaage-Nilsen M et al. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014; 15: 47.
4. De Forni M, Bugat R, Sorbette F et al. Cardiotoxicity of continuous intravenous infusion of 5-fluorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases. Bull Cancer 1990; 77 (5): 429–38.
5. Südhoff T, Enderle MD, Pahlke M et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 2004; 15 (4): 661–4.
6. Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Int Med J 2010; 40 (4): 303–7.
7. Grunwald MR, Howie L, Diaz LA Jr. Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature. J Clin Oncol 2012; 30 (2): e11–e14.
8. Smith SA, Auseon AJ. Chemotherapy-induced takotsubo cardiomyopathy. Heart Fail Clin 2013; 9 (2): 233–42.
9. Cerny J, Hassan A, Smith C et al. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. Clin Colorectal Cancer 2009; 8 (1): 55–8.
10. Ambrosy AP, Kunz PL, Fisher GA et al. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol 2012; 110 (11): 1623–6.
11. Boyle JJ, Wilson B, Bicknell R et al. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol 2000; 192 (2): 234–42.
12. Coward J, Maisey N, Cunningham D. The effects of capecitabine in Raynaud’s disease: a case report. Ann Oncol 2005; 16 (5): 835–6.
13. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58 (4): 487–93.
14. Polk A, Vaage-Nilsen M, Vistisen K et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013; 39 (8): 974–84.
15. Rowinsky EK, McGuire WP, Guarnieri T et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9 (9): 1704–12.
16. Schrader C, Keussen C, Bewig B et al. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res 2005; 10 (11): 498–501.
17. Shah K, Gupta S, Ghosh J et al. Acute non-ST elevation myocardial infarction following paclitaxel administration for ovarian carcinoma: a case report and review of literature. J Cancer Res Ther 2012; 8 (3): 442–4.
18. Berliner S, Rahima M, Sidi Y et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990; 8 (6): 583–6.
19. Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anti Cancer Drugs 2008; 19 (9): 927–9.
20. Karabay KO, Yildiz O, Aytekin V. Multiple coronary thrombi with cisplatin. J Invasive Cardiol 2014; 26 (2): E18–E20.
21. Togna GI, Togna AR, Franconi M et al. Cisplatin triggers platelet activation. Thromb Res 2000; 99 (5): 503–9.
22. Dieckmann KP, Gerl A, Witt J et al. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol 2010; 21 (8): 1607–11.
23. Ito D, Shiraishi J, Nakamura T et al. Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy. Heart Vessels 2012; 27 (6): 634–8.
24. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18 (8): 1725–32.
25. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treat-ment for testicular cancer. J Clin Oncol 2003; 21 (8): 1513–23.
26. Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28 (30): 4649–57.
27. Feldman DR, Schaffer WL, Steingart RM. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Cancer Netw 2012; 10 (4): 537–44.
28. Gietema JA, Meinardi MT, Messerschmidt J et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355 (9209): 1075–6.
29. Nuver J, Smit AJ, Sleijfer DT et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40 (5): 701–6.
30. Oh JH, Baum DD, Pham S et al. Long-term complications of platinum-based chemotherapy W.J. in testicular cancer survivors. Med Oncol 2007; 24 (2): 175–81.
31. Kachel DL, Martin. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther 1994; 268 (1): 42–6.
32. Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141 (6): 758–63.
33. Katayama M, Imai Y, Hashimoto H et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol 2009; 54 (2): 330–4.
34. Stefenelli T, Kuzmits R, Ulrich W et al. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J 1988; 9 (5): 552–6.
35. Soultati A, Mountzios G, Avgerinou C et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev 2012; 38 (5): 473–83.
36. Schwarzer S, Eber B, Greinix H et al. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J 1991; 12 (6): 748–50.
37. Doll DC, List AF, Greco FA et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105 (1): 48–51.
38. Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987; 19 (3): 253–6.
39. Panella M, Ross JE, Garvin K et al. Cardiac sudden death as a result of acute coronary artery thrombosis during chemotherapy for testicular carcinoma. J Forensic Sci 2010; 55 (5): 1384–8.
40. Gallagher H, Carroll WM, Dowd M et al. The effects of vinblastine on endothelial cells. Endothelium 2008; 15 (1): 9–15.
41. Schutz FA, Je Y, Azzi GR et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011; 22 (6): 1404–12.
42. Ranpura V, Hapani S, Chuang J et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010; 49 (3): 287–97.
43. Chen XL, Lei YH, Liu CF et al. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One 2013; 8 (6): e66721.
44. Choueiri TK, Schutz FA, Je Y et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010; 28 (13): 2280–5.
45. Qi WX, Shen Z, Tang LN et al. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis. Crit Rev Oncol Hematol 2014; 92 (2): 71–82.
46. Kappers MH, van Esch JH, Sluiter W et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010; 56 (4): 675–81.
47. Winnik S, Lohmann C, Siciliani G et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis–implications for cardiovascular safety. Int J Cardiol 2013; 168 (3): 2453–61.
48. Kappers MH, Smedts FM, Horn T et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 2011; 58 (2): 295–302.
49. Kappers MH, de Beer VJ, Zhou Z et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012; 59 (1): 151–7.
50. Arima Y, Oshima S, Noda K et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol 2009; 54 (3): 512–5.
51. Porto I, Leo A, Miele L et al. A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol 2010; 7 (8): 476–80.
52. Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz 2011; 36 (4): 348–51.
53. Franco TH, Khan A, Joshi V et al. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag 2008; 4 (6): 1367–70.
54. Numico G, Sicuro M, Silvestris N et al. Takotsubo syndrome in a patient treated with sunitinib for renal cancer. J Clin Oncol 2012; 30 (24): e218–e220.
55. Sen F, Yildiz I, Basaran M et al. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib. J BUON 2013; 18 (3): 775–81.
56. Chintalgattu V, Rees ML, Culver JC et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med 2013; 5 (187): 187ra69.
57. Van der Veldt AA, de Boer MP, Boven E et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anti Cancer Drugs 2010; 21 (4): 439–46.
58. Pantaleo MA, Mandrioli A, Saponara M et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer 2012; 12: 231.
59. Ropert S, Vignaux O, Mir O, Goldwasser F. VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption. Invest New Drugs 2011; 29 (6): 1497–9.
60. Meyer T, Robles-Carrillo L, Robson T et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009; 7 (1): 171–81.
61. Aichberger KJ, Herndlhofer S, Schernthaner GH et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86 (7): 533–9.
62. Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012; 12 (5): 337–40.
63. Levato L, Cantaffa R, Kropp MG et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol 2013; 90 (6): 531–2.
64. Cortes JE, Kantarjian H, Shah NP et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367 (22): 2075–88.
65. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011; 86 (7): 610–1.
66. Coon EA, Zalewski NL, Hoffman EM et al. Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol 2013; 88 (6): 534–5.
67. Breccia M, Colafigli G, Molica M et al. Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. Am J Hematol 2015; 90 (5): E100–E101.
68. Chislock EM, Ring C, Pendergast AM. Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci U S A 2013; 110 (30): 12432–7.
69. Teragawa H, Hondo T, Amano H et al. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996; 37 (6): 905–15.
70. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011; 37 (4): 300–11.
71. Kruit WH, Eggermont AM, Stoter G. Interferon-alpha induced Raynaud’s syndrome. Ann Oncol 2000; 11 (11): 1501–2.
72. Al-Zahrani H, Gupta V, Minden MD et al. Vascular events associated with alpha interferon therapy. Leuk Lymphoma 2003; 44 (3): 471–5.
73. Thacker SG, Zhao W, Smith CK et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 2012; 64 (9): 2975–85.
74. Lancellotti P, Nkomo VT, Badano LP et al. European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013; 14: 721–40.
75. Zamorano JL, Lancellotti Р, Munoz DR et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; 37: 2768–801.
76. Piccirillo JF, Tierney RM, Costas I et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291 (20): 2441–7.
77. Chazova I.E., Oshchepkova E.V., Zhernakova Iu.V. Diagnostika i lechenie arterial'noi gipertonii. Klinicheskie rekomendatsii. Kardiologich. vestn. 2015; 1: 3–31. [in Russian]
78. Colt JS, Schwartz K, Graubard BI et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 2011; 22: 797–804.
79. Milan A, Puglisi E, Ferrari L et al. Arterial hypertension and cancer. Int J Cancer 2014; 134: 2269–77.
80. Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20: 807–15.
81. Qi WX, He AN, Shen Z et al. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 2013; 76: 348–57.
82. Qi WX, Lin F, Sun YJ et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a metaanalysis. Cancer Chemother Pharmacol 2013; 71: 431–9.
83. Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23: 460–8.
84. Li Y, Li S, Zhu Y et al. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2014; 16 (3): 177–85.
85. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009; 48: 9–17.
86. Qi WX, Shen Z, Lin F et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 2013; 75: 919–30.
87. Wang Z, Xu J, Nie W et al. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol 2014; 70: 225–31.
88. Qi WX, Fu S, Zhang Q et al. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis. J Cancer Res Ther 2016; 12 (2): 775–81.
89. Qi WX, Shen Z, Tang LN et al. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. Clin Drug Invest 2014; 34 (4): 231–40.
90. Wicki A, Hermann F, Prкtre V et al. Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study. Oncol Res Treat 2014; 37: 230–6.
91. Hamnvik OP, Choueiri TK, Turchin A et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015; 121: 311–9.
92. Tomita Y, Uemura H, Fujimoto H et al. Japan Axitinib Phase II Study Group. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 2011; 47: 2592–602.
93. Small HY, Montezano AC, Rios FJ et al. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol 2014; 30: 534–43.
94. Mourad JJ, Des Guetz G, Debbabi H et al. Blood pressure rise following angiogenesis inhibition bybevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927–34.
95. Facemire CS, Nixon AB, Griffiths R et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009; 54: 652–8.
96. Ciuffetti G, Schillaci G, Innocente S et al. Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J Hypertens 2003; 21: 2297–303.
97. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008; 266 (1): 37–52.
98. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129–36.
99. Scartozzi M, Galizia E, Chiorrini S et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009; 20 (2): 227–30.
100. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with sunitinib. J Natl Cancer Inst 2011; 103 (9): 763–73.
101. De Souza VB, Silva EN, Ribeiro ML et al. Hypertension in Patients with Cancer. Arq Bras Cardiol 2015; 104 (3): 246–52.
102. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
103. Maitland ML, Bakris GL, Black HR et al. Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.
104. Herrmann J, Yang EH, Iliescu CA et al. Vascular Toxicities of Cancer Therapies The Old and the New – An Evolving Avenue. Circulation 2016; 133: 1272–89.
105. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151–6.
106. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687–91.
107. McKay RR, Rodriguez GE, Lin X et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015; 21 (11): 2471–9.
108. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006; 48: 622–7.
109. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010; 7: 564–75.
110. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231–47.
111. Tamargo J, Caballero R, Delpon E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 2015; 38: 129–52.
112. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsedacute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–60.
113. Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associatedwith tyrosine kinase inhibitors. Oncologist 2013; 18: 900–8.
114. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013; 36: 295–316.
115. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007; 25: 3362–71.
116. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillationin cancer. J Am Coll Cardiol 2014; 63: 945–53.
117. Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventriculararrhythmias and the prevention of sudden cardiac death: the Task Forcefor the Management of Patients with Ventricular Arrhythmias and the Preventionof Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsedby: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793–867.
118. Al-Khatib SM, LaPointe NM, Kramer JM et al. What clinicians should knowabout the QT interval. JAMA 2003; 289: 2120–7.
119. Bates SE, Rosing DR, Fojo T et al. Challenges of evaluating the cardiaceffects of anticancer agents. Clin Cancer Res 2006; 12: 3871–4.
120. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrialfibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893–962.
121. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467–507.
122. Larsen TB, Nielsen PB, Skjoth F et al. Non-vitamin K antagonistoral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One 2014; 9 (12): e114445.
123. Limsuwan A, Pakakasama S, Rochanawutanon M et al. Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology 2006; 105: 188–94.
124. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009; 33: 861–4.
125. Mattei D, Feola M, Orzan F et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009; 43: 967–8.
126. Montani D, Bergot E, Günther S et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128–37.
127. Dumitrescu D, Seck C, ten Freyhaus H et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011; 38: 218–20.
128. Guignabert C, Montani D. Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. Eur Respir J 2013; 41: 3–4.
129. Galie N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67–119.
130. Simonneau G, Gatzoulis MA, Adatia I et al. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25): 34–41.
131. Ranchoux B, Gunther S, Quarck R et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol 2015; 185: 356–71.
132. Chazova I.E., Avdeev S.N., Tsareva N.A. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniiu legochnoi gipertonii. Ter. arkhiv. 2014; 9: 4–23. [in Russian]

И.Е.Чазова1, С.А.Тюляндин2, М.В.Виценя*1, М.Г.Полтавская3, М.Ю.Гиляров3, Т.В.Мартынюк1, А.Г.Овчинников1, Е.П.Панченко1, Ю.А.Федоткина1, М.Б.Стенина2, О.П.Трофимова2,4, Ф.Т.Агеев1

1 Институт клинической кардиологии им. А.Л.Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России. 121552, Россия, Москва, ул. 3-я Черепковская, д. 15а;
2 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
3 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, 
д. 8, стр. 1;
4 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*marinavitsenya@gmail.com

________________________________________________

I.Ye.Chazova1, S.A.Tyulyandin2, M.V.Vitsenia*1, M.G.Poltavskaya3, M.Yu.Gilyarov3, T.V.Martynyuk1, A.G.Ovchinnikov1, E.P.Panchenko1, Yu.A.Fedotkina1, M.B.Stenina2, O.P.Trophimova2, 4, F.T.Ageev1

1 A.L.Myasnikov Institute of Clinical Cardiology National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15a;
2 N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23;
3 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
4 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*marinavitsenya@gmail.com